Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia.

Author:
  • Carl Ekman
  • Anders Gottsäter
  • Bengt Lindblad
  • Björn Dahlbäck
Publishing year: 2010
Language: English
Pages: 873-876
Publication/Series: Clinical Biochemistry
Volume: May 4
Document type: Journal article
Publisher: Elsevier

Abstract english

INTRODUCTION: Critical limb ischemia (CLI) is a severe peripheral arterial disease, characterized by rest pain, ulcers and gangrene in the legs. Gas6 is a vitamin K-dependent protein, which binds and activates the tyrosine kinase receptor Axl. Gas6-mediated Axl-signaling influences endothelial activation, neointima formation and immune regulation. Axl can be cleaved and soluble Axl (sAxl) is detectable in circulation. DESIGN AND METHODS: We quantified plasma concentrations of Gas6 and sAxl in 189 CLI patients and 204 controls. RESULTS: Gas6 and sAxl concentrations were increased in the CLI patients (p<0.0001) and correlated to C-reactive protein, interleukin-6, tumor necrosis factor alpha and neopterin. Patients who died within three years of sampling (n=84) had increased concentrations of Gas6 and sAxl as compared to survivors (p=0.0009 and p=0.0011). CONCLUSIONS: Plasma concentrations of Gas6 and sAxl correlate to inflammation and predict survival. This indicates that Gas6 and sAxl have a role in CLI, presumably connected to the inflammatory process.

Keywords

  • Biochemistry and Molecular Biology

Other

Published
  • Clinical Chemistry, Malmö
  • Vascular Diseases - Clinical Research
  • ISSN: 1873-2933
E-mail: carl [dot] ekman [at] med [dot] lu [dot] se

Postdoctoral fellow

Genomics, Diabetes and Endocrinology

33

Research project participant

Genomics, Diabetes and Endocrinology

33

Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00